Project Grant R01CA315671
Award Date 8/19/26
Completion Date 6/30/31
Dollars Obligated $488K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New Haven, CT 06519, USA
Similar Awards
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded Yale University $696,189 on April 7, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate mechanisms of CD8 T cell differentiation in tumor-draining lymph nodes. The research examines how CD8 T cells—specifically progenitor-exhausted (TPEX) cells housed in tumor-draining lymph nodes associated with lung adenocarcinoma—maintain stemlike properties and...
- Federal Grant Award Summary The National Cancer Institute awarded Yale University a $478,532 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective September 1, 2025, through August 31, 2027. This research initiative will investigate the biological and clinical significance of spatial immune heterogeneity in non-small cell lung cancer (NSCLC), with particular focus on characterizing how the spatial distribution of tumor-infiltrating lymphocytes (TILs) and tertiary...
- The National Cancer Institute awarded Yale University $560,087 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to define and target mechanisms of the neurolysin-KIF11-WNT3A axis driving therapy resistance in prostate cancer. The award funds research into how prostate cancer cells adapt to androgen receptor-targeted therapies and remodel the tumor microenvironment to undermine therapeutic activity. The work will comprehensively define the molecular mechanisms by...
- The National Cancer Institute awarded Cold Spring Harbor Laboratory $675,617 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate intercellular metabolic and signaling mechanisms of brain cancer-glia communication driving glioblastoma progression. The project examines how glioblastoma cells reprogram brain microglia—the brain's resident immune cells—to create an immunosuppressive tumor microenvironment that promotes tumor growth. The research focuses on an...
- The National Cancer Institute awarded Yale University $607,690 on May 6, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an MR-based platform for simultaneous intracellular pH (PHI) and extracellular pH (PHE) imaging in glioblastoma multiforme (GBM). The research aims to distinguish glycolytic and oxidative tumor phenotypes by measuring transmembrane pH gradients, which are larger in tumors than normal tissue and vary between metabolic phenotypes....
- The National Institutes of Health National Cancer Institute awarded Yale University $684,252 on June 2, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the functions and mechanisms of innate lymphoid cells type 2 (ILC2s) in trained immunity. The research examines how ILC2s in bone marrow establish and sustain trained immunity—an epigenetic memory process in hematopoietic stem and progenitor cells that produces robust immune responses to subsequent inflammatory...
- The National Cancer Institute awarded Duke University $1.882 million under the Cancer Biology Research program (CFDA 93.396) on September 23, 2025, to integrate genome-wide association study data with single-cell omics to reveal the cellular effectors of glioblastoma predisposition. Work will be performed in Durham, North Carolina, with a completion date of August 31, 2029. The Cancer Biology Research program funds fundamental information on the cause and nature of cancer, encompassing cancer...
- The National Cancer Institute (within the Department of Health and Human Services National Institutes of Health) awarded Yale University $615,287 under the Cancer Biology Research program (CFDA 93.396) on July 10, 2026, to investigate aberrant glycosylation pathways as a therapeutic target in non-small cell lung cancer with KRAS/LKB1 co-mutations. The research focuses on the ALG5 gene's oncogenic role in the N-glycosylation biosynthesis pathway and its contribution to aggressive lung...
- The National Cancer Institute awarded Yale University $100,228 on December 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research training and biomedical career development in cancer research. Yale will conduct basic research on the regulation of membrane-chromatin interactions during mitotic nuclear formation and their role in cancer cell survival. The project investigates how endoplasmic reticulum membranes and LEM-domain proteins, including LEMD2 and emerin,...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded Albert Einstein College of Medicine $431,970 under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2026. The recipient will conduct research into epigenetic regulation of glioblastoma stem-like cells, specifically exploring how the arginine methyltransferase CARM1 controls NGFR and NTRK signaling pathways. The work encompasses two primary aims: testing...